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Summary In this study we report detection of mdrl gene expression in the liver metastases of 7/11 patients
with colon carcinoma and characterise the MDR phenotype associated with a panel of 19 human colon
carcinoma cell lines. Within this panel, mdrl mRNA biosynthesis and surface localisation of Pgp were assessed
with respect to MDR functionality where the cell lines are representative of different clinical stages of tumour
progression, metastatic potential and differentiation. The data indicates that constitutive levels of mdrl
mRNA/Pgp expression may not necessarily result in the functional expression of the MDR phenotype. While
low levels of mdrl mRNA/Pgp were detected in 5/8 well differentiated colon cell lines, only 2/8 were
functionally MDR. In contrast, 10/11 moderate and poorly differentiated lines expressed mdrl mRNA/Pgp
and of these, 9/11 were functionally MDR. The phosphorylation status of the mature 170 kD P-glycoprotein
and the surface localisation of this glycoprotein showed the strongest correlation with functionality. Analysis
of cell lines for cross-resistance and chemosensitivity profiles against a battery of chemotherapeutic drugs
suggests multiple mechanisms, in addition to Pgp, contribute to the overall resistance of colorectal cancer.
Colorectal cancer is second only to lung cancer as the leading
cause of death due to cancer in the United States. Although
surgery is successful in a large percentage of these cases, the
survival rate deteriorates rapidly if the tumour has invaded
through the serosa or has metastasised to regional lymph
nodes or liver (Silverburg & Lubera, 1986). As a rule, chemo-
therapy is the first line of treatment for disseminated disease,
however colorectal cancer is refractory to most chemothera-
peutic agents (Haller, 1988). Unfortunately, very little is
known about the mechanisms responsible for the intrinsic
drug resistance of this disease. Successful chemotherapy will
ultimately depend on the elucidation of these mechanisms.
In vitro studies utilising tumour cells that acquired resis-
tance by selection with anti-tumour drugs have identified a
form of resistance (i.e. multidrug resistance or MDR) that is
characterised by decreased sensitivity to a broad range of
structurally and mechanistically dissimilar natural product
anti-cancer drugs (e.g. doxorubicin, vincristine, etoposide,
Riehm & Biedler, 1971; Bech-Hansen et al., 1986). These
compounds represent some of the most effective anti-cancer
agents currently available for treatment of a wide range of
malignancies. The hallmark of MDR is decreased drug accu-
mulation that is related to the increased expression of the
mdrl gene product, a 170 kD membrane glycoprotein ternied
Pgp (Kartner et al., 1983). The predicted amino acid
sequence of mdrl suggests that Pgp functions as an energy
dependent efflux-pump (Chen et al., 1986) and is consistent
with studies showing that Pgp can bind drug and facilitate
efflux by an ATP dependent process (Cornwell et al., 1986).
Increased expression of mdrl mRNA/Pgp has been observ-
ed clinically in a variety of cancers (e.g. multiple myelomas,
sarcomas, neuroblastomas, breast) that relapsed following an
initial response to chemotherapy (Ma et al., 1987; Gerlach et
al., 1987; Dalton et al., 1989; Goldstein et al., 1990), a
situation that is analogous to in vitro models for establishing
resistant cell lines. Pgp has also been found localised to the
lumenal surface of normal epithelial cells lining the colon,
kidney, pancreas and bile ducts in addition to its localisation
in the adrenal gland, placenta and vascular endothelial cells
in the testes and brain (Thiebaut et al., 1987; Yang et al.,
1989; Cordon-Cardo et al., 1989, 1990). This pattern of
distribution is consistent with a physiological role for Pgp in
the protection of normal tissues against toxicants. Expression
of mdrl mRNA has been frequently detected in tumours
derived from these tissues (Fojo et al., 1987a,b; Lai et al.,
1989; Goldstein et al., 1989), before the patients received
chemotherapy, suggesting that MDR may also be responsible
for the inherent resistance of these tumours. Nevertheless, it
is difficult to establish a causal relationship between intrinsic
clinical resistance and total mdrl mRNA/Pgp expression
levels given the possibility that tumour specimens are often
contaminated with the normal mdrl expressing tissues, and
that mdrl mRNA/Pgp may not be expressed uniformly
throughout the tumour (Schlaifer et al., 1990; Weinstein et
al., 1991). This may explain the high degree of variability in
mdrl mRNA expression reported for solid tumours (Fojo et
al., 1987a,b; Lai et al., 1989; Goldstein et al., 1989). It is also
not known whether the level of Pgp found in untreated
samples is sufficient to confer resistance, and/or whether the
Pgp expressed in these tumours is fully functional. Finally, it
is likely that additional drug resistance mechanisms (e.g.,
glutathione-S-transferase, topoisomerase, etc.) contribute to
the overall level of intrinsic tumour drug resistance (Kramer
et al., 1988, 1989).
In this manuscript we report detection of mdrl mRNA in
the liver metastasis of patients with colon carcinoma and
evaluate the association of mdrl gene expression with Pgp
biosynthesis and function (i.e. verapamil-inducible drug
accumulation and cytotoxicity) in 19 human colon carcinoma
cell lines.
Materials and methods
Cell lines
Human colorectal carcinoma cell lines were maintained in
culture in Dulbecco's modified Eagles medium (DMEM)
supplemented with 5% foetal calf serum. Cell lines DLD-1,
Clone A and Clone D were provided by Dr D. Dexter, E.I.
DuPont DeNemours Co, Wilmington, DE, USA. Cell line
MIP 101 was established by Dr Niles in collaboration with
G.D. Steele. The Moser cell line was kindly provided by Dr
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M. Brattain, Baylor College, Houston, TX, USA. All the
aforementioned cell lines were established from tumour tissue
prior to any chemotherapy (personal communications). The
remaining cell lines were obtained from the American Type
Culture Collection (ATCC).
Northern blot analysis
Total cellular RNA was isolated from adherent cells by
scraping in guanidium isothiocyanate followed by centrifuga-
tion through cesium chloride (Chirgwin et al., 1979). Fresh
tumour and normal tissue were treated to minimise RNA
digestion by snap freezing in liquid nitrogen. Frozen tissues
were pulverised on a metal surface placed on a bed ofdry ice
prior to homogenisation. Equivalent amounts of RNA (10
itg/lane) were electrophoresed through a denaturing 1%
agarose/formaldehyde (7%) gel and stained with ethidium
bromide, to check for RNA integrity and equal loading,
prior to transfer to GeneScreen Plus membrane (NEN, Bos-
ton, MA, USA). Filters were prehybridised for 60 min at
60°C in 50% formamide, 7% SDS, 0.25 M sodium phosphate
pH 7.2, 0.25M NaCl, 1 mM EDTA, 1I00 tgml-I denatured
salmon sperm DNA, 200pgml-' tRNA followed by hybrid-
isation for 18 h at 60°C in the same buffer containing 2 x 106
c.p.m. ml1- of labelled riboprobe. A synthetic riboprobe was
prepared by SP6 polymerase transcription of the pHDR5A
pGEM human mdr probe (Ueda et al., 1987). Filters were
washed twice for 60 min in PSE (0.25 M sodium phosphate,
pH 7.2, 2% SDS, 1 mM EDTA) followed by final wash in
30 mM NaCl, 3 mM sodium citrate, 0.1% SDS at 65%.
Filters were exposed to Kodak X-AR5 film at -70°C for
1-3 days.
Immunoprecipitation ofP-glycoprotein
Subconfluent dishes of colon carcinoma cell lines were wash-
ed twice in phosphate buffered saline (PBS) and incubated
for 1 h in methionine or phosphate-free Dulbecco's modified
Eagles medium (DMEM) followed by incubation (3 or 18 h)
in medium containing 35S-methionine (150 yCiml-') or 32p
Orthophosphate (200JACi ml-'). Metabolically labelled cells
were rinsed briefly in PBS, and lysed in PBSTDS buffer (PBS
pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, 2 mM phenylmethylsulfonylfluoride,
10 U ml-' aprotinin). Lysis was carried out for 20 min at
4°C, followed by shearing of lysates through a 24 gauge
needle. Lysates were clarified in a microfuge for 20 min at
40C, supernatants were removed and a 10IL aliquot was
taken for protein estimation using the bovine serum albumin
protein assay system (Pierce, Rockford, IL, USA). Prior to
immunoprecipitation samples were standardised for protein
concentration using 400iLg for each cell line. Lysates were
incubated overnight at 4°C with mdrl polyclonal antibody
(Oncogene Science, Manhasset, NY, USA), followed by the
addition of protein A Sepharose beads and a further 90 min
incubation. Immune complexes were washed three times in
PBSTDS, three times in 0.1 PBS, followed by incubation in
standard sample buffer for 20 min at room temperature. All
samples were run on 7.5% polyacrylamide gels, dried and
exposed for 1-3 days to X-ray film.
Functional assays
Drug accumulation studies The effect of the Pgp antagonist
verapamil (OiLgml-'), on [3H]-daunorubicin (1O im; specific
activity 1 mCi/10 ILM) accumulation was determined in repli-
cate suspensions of colon cells (2 x 106 cellsml-') using a
standard silicone oil technique for separating cells from
extracellular medium, as previously described (Kramer et al.,
1988). Initial time vs uptake studies showed that [3H]-dauno-
rubicin accumulation reached a plateau between 60-90min
(data not shown). In all subsequent studies, the 90 min time
point was used to quantitate the fold increase in drug
accumulation (nmoles/106 cells) caused by the verapamil
treatment. Although this procedure does not take into
account possible differences in cell volumes, drug metabolism
or passive drug permeation coefficient (Spoelstra et al., 1992),
it is adequate for our purpose of comparing multiple cell
lines, with each cell line serving as its own control.
Drug sensitivity studies The sensitivity of the cell lines to
doxorubicin in the presence and absence of verapamil (10fig
ml-') was determined in monolayers of cells using the sulfor-
hodamine B (SRB) protein binding colorimetric cytotoxicity
assay (SRB) described by Skehan et al. (1990). In this assay,
1 x I04 cells were plated in each well of a 96-well microtitre
plastic, and the following day the cells were incubated with
drugs for 3 h, washed twice in phosphate-buffered saline and
fresh medium was added. Three hour drug incubations were
used to minimise the toxicity of prolonged verapamil treat-
ment. Cells were fixed in 10% trichloroacetic acid (TCA) and
stained with SRB 4 days after drug treatment. Absorbance
values were recorded with a microplate reader (molecular
Devices) and values were reported as per cent of control
(T/C) from the means of duplicate determinations. IC50
values in the absence and presence of verapamil were calcu-
lated and dose modifiying factors (DMF) were determined
(IC50 control/IC50 + verapamil). Chemosensitivity profiles
against a panel of chemotherapeutic agents were conducted
using a slight modification of this procedure. In these studies,
drug treatments were for 48 h and duplicate plates of cells
were fixed with TCA at the time ofdrug addition to establish
To values, as described by Monks et al. (1991). The effect of
drug treatments over a range of concentrations were cal-
culated using the formula, T-To/C-To, to determine the IC50
value.
Flow cytometry
Surface staining of cells for P-glycoprotein expression was
accomplished using the 4E3.16 anti-P-glycoprotein mono-
clonal antibody (Arceci et al., 1993). Adherent cells were
collected in cold phosphate buffered saline (PBS) by gentle
scraping with a rubber policeman. Cells were washed twice in
cold PBS and 1 x 106 cells were resuspended in 100 yl of PBS
containing 1:1 dilution of human serum with PBS and incu-
bated at 4°C for 30 min to block Fc receptors. Two milliliters
of PBS were then added to the cells which were collected by
centrifugation at 600g for 3 min. Pelleted cells were re-
suspended in 1001l of PBS containing 2% goat serum and
10 g ml-' of the anti P-glycoprotein antibody 4E3.16 or an
IgG2a isotype matched control antibody. This mixture was
incubated for 30 min at 4°C, cells were washed twice with
cold PBS, followed by resuspension in 100jlI of PBS contain-
ing 2% goat serum and FITC-labelled goat-antimouse Ig
(Fab)2 fragment (TAGO) at a 1:30 dilution. Cells were incu-
bated with the second antibody for 30min at 4°C in the
dark, followed by two washes in cold PBS and fixation in 2%
paraformaldehyde prior to analysis. The level of P-glyco-
protein expression was determined using a Becton-Dickinson
FASCAN II using LYSYS software application.
Results
mdrl mRNA expression in metastatic colon cancer
mdrl mRNA was measured in 16 colon tumour specimens
(Figure 1) that included four primary lesions, 11 liver and
one lymph node metastasis, that were obtained from patients
before they received chemotherapy. Northern blot analysis
revealed a single 4.5 kb mRNA (mdrl) present in most tissues
(Figure 1) with the exception of one liver metastasis in which
we detected a second transcript of approximately five kilo-
bases. Integrity of RNA, equal loading and transfer com-
pletion was confirmed by ethidium bromide staining (Figure
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Figure 1 Northern blot analysis showing comparative levels of mdrl transcripts in normal colon mucosa (N, nI), primary colon
tumours (1'), lymph node metastasis (ly) and liver metastasis of colon tumours. The integrity and comparative loading of RNA is
shown in the ethidium bromide stained gel in each panel. a, mdrl expression in adjacent normal mucosa (N) and primary colon
tumours (1°) from three patients, b, detection ofmdrl transcripts in normal (nl), tumour (1°) and lymph node metastasis (ly) from a
single patient. From both panels a 4.5 kb mdrl message is detected in seven of 11 liver metastases with an additional larger message
detected in patient 1 a.
Levels ofexpression ofmdrl mRNA varied widely between
tumour samples. Nevertheless, mdrl mRNA was readily
detected in 7/11 liver metastases although no mdrl message
was detected in the one lymph node metastasis that was
evaluated. In two additional patients, we were able to obtain
both the primary tumour and the corresponding liver metas-
tasis. In one case, the primary tumour and the corresponding
liver metastasis expressed comparable levels of mdrl tran-
scripts; in the second case mdrl mRNA levels were much
higher in the metastasis of the second patient (data not
shown). When possible, tumour samples were run in parallel
with adjacent normal mucosa obtained at the time of sur-
gery. The relative level of mdrl mRNA detected in primary
tumours and adjacent normal tissues also varied consid-
erably, with normal tissues expressing higher levels in two of
the three pairs evaluated (Figure 1, panel a).
Characterisation ofMDR in human colon carcinoma cell lines
Although every attempt has been made to standardise loaded
samples in Northern blot analysis, heterogeneity within
tumours and variability between tumour content make inter-
pretations of results difficult. Immunohistochemistry and in
situ hybridisation have been used previously to resolve this
problem, however, such approaches cannot relate Pgp expres-
sion to functionality. To clarify this issues we have used a
panel of colon carcinoma cell lines representing a more
homogeneous starting cell population for the analysis of
mdrl mRNA/Pgp expression and Pgp function. Nineteen
human colon carcinoma cell lines were classified according to
differentiation state based on a variety of established criteria
that include the histopathology of the original tumour and
subsequent xenografts, carcinoembryonic antigen (CEA) pro-
duction and, in some cases, invasive potential (Table I). In
this way, the panel of human colon cell lines represents a
range of differentiation phenotypes, in vitro and in vivo, with
different invasive and metastatic potentials. From the data
presented in Table I, histologically well differentiated cell
lines exhibited many characteristics distinct from the pheno-
type expressed by histologically moderate or poorly differ-
entiated cells.
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Table I Characterisation of human colorectal cell panel
Differentiation CEA productionb Invasion through
Cell line statusa (ng/ml/l06 cells) matrigel
CX-1 M/W 35 31%
HTB-39 (HT29) M/W 7 NDd
CCL238 (SW1417) N.T.C 24 38%
CL187 (LS180) M/W 525 ND
CL188 (LS174T) M/W 5119 ND
CCL229 (LoVo) M/W 882 ND
HTB-37 (CaCo-2) M/W 27 ND
CCL233 (SW1116) M/W 120 ND
CCL-221 (DLD-1) M/P 1.2 ND
Moser M/P <0.5 ND
Clone D M/P <0.5 ND
CCL235 (SW837) M/P 7 47%
CCL231 (SW48) M/P <0.5 ND
CCL227 (SW620) P <0.5 ND
CCL228 (SW 480) P 0.7 79%
Clone A P <0.5 100%
CCL222 P 2.5 ND
CCL220.1 P <0.5 ND
MIP 101 P <0.5 75%
'Differentiation established from xenograft study. M/W=moderate/well; M/
P = moderate/poor; P = poor. bCEA was determined on conditioned media using the
Hoffman LaRoche radioimmunoassays. cExpressed as apercentage ofCloneAvalues
from Daneker et al. (1989). dND = not determined. CNT = non-tumorigenic.
Expression ofmdrl mRNA and Pgp in colon cells
Northern blot analysis of RNA from a representative panel
of colon cell lines showed expression of a 4.5 kb mdrl tran-
script in the majority of cell lines evaluated (12/19) (Figure
2). Mdrl mRNA was detected in only 3/8 well differentiated
cell lines, and in 9/11 of the moderate and poorly different-
iated cell lines (Table II). Higher levels of mdrl mRNA were
apparent in the moderate and poorly differentiated cell lines
with the highest levels found in Clone A and MIP 101, which
were derived from, and are classified as, representative of
poorly differentiated phenotypes (Dexter et al., 1979, 1981;
Niles et al., 1987). The wide range of mdrl mRNA levels
detected in colon cell lines (Table II) was analogous to our
observations with colon tumour tissue (Figure 1).
Pgp biosynthesis was established after overnight labelling
of cells with "5S-methionine followed by immunoprecipitation
with a polyclonal mdrl antibody (Figure 3, Table II). In a
number of cell lines small amounts of the 170 kd P-glyco-
protein were detected where no mdrl mRNA was detected in
repeated Northern blot analysis (e.g. CaCo-2, Figure 3). Pgp
was detected in 5/8 well differentiated and 9/10 moderate and
poorly differentiated cell lines tested. In comparison to well
differentiated colon cells, the moderate and poorly different-
iated cell lines displayed higher levels ofPgp, proportional to
the respective cellular levels of mdrl mRNA detected (Table
II). The highest levels of Pgp were found in the poorly
differentiated Clone A and MIP 101 cell lines (Figure 3, top
panel). The antibody used in these experiments immuno-
precipitates a second protein of >200 kD. This protein
appears unrelated to Pgp, since it is precipitated from cell
lines which do not express detectable P-glycoprotein (HT29,
CCL238). However, it serves as a useful internal control for
verification of protein standardisation in all experiments.
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Figure 2 Northern blot analysis showing level of 4.5 kb mdrl
transcript in a representative panel of colon carcinoma cell lines.
Repetition of experiments following overnight labelling with
32P-orthophosphate confirmed previous observations of phos-
phorylation of the 170 kd Pgp (Figure 3, lower panel), where
the degree of phosphorylation was found to be a good
indicator of Pgp pump activity (Table II) suggesting that
phosphorylation is a critical post-translational event in estab-
lishing Pgp function.
Altered Pgp expression in colon cell lines
Previous work by other investigators have demonstrated that
Pgp is synthesised as a 140 kd precursor which matures, via
N-linked glycosylation, to a 170 kd membrane associated Pgp
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Figure 3 Immunoprecipitation ofP-glycoprotein from a panel of
colon carcinoma cell lines. Cells labelled for 18 h with 35S-
methionine (upper panel) or 32P-orthophosphate (lower panel)
prior to precipitation. In both experiments P-glycoprotein (Pgp)
is resolved as the mature 170 kD form.
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Table II Characterisation of MDR in representative panel of human colon carcinoma cell lines
[3H]-Daun (nmoles/l06 cells)a Dox IC50 (fLM)b mdrl mRNA/ Pgp surface
Cell lines - Ver + Ver (DMF)C - Ver + Ver (DMF)C Pgp biosynthesisd expressione
Moderate/Well
CX-1 1.89 1.93 (1.0) 0.63 0.59 (1.0) 0/0
HT29 2.17 2.17 (1.0) 0.05 0.05 (1.0) 0/0 _
CCL238 2.29 1.84 (0.8) ND' ND 0/0
CL187 1.46 1.49 (1.0) ND ND 0/+
CL188 2.24 2.66 (1.2) 0.28 ND +/+ +
LoVo 1.53 1.25 (0.8) ND ND +/+ +/-
CaCo-2 2.34 2.42 (1.0) 1.67 1.67 (1.0) 0/+
CCL233 0.97 1.24 (1.3) ND ND +/+ +
Moderate/Poor
DLD-1 1.58 1.94 (1.3) 0.37 0.33 (1.1) + ++/+ -
Moser 0.72 1.83 (2.5) 1.10 0.34 (3.0) +++/+++ ++++-
Clone D 0.22 1.60 (7.3) ND ND + + +/+
CCL235 0.61 1.07 (1.7) ND ND + +/+ +
CCL231 1.15 2.06 (1.8) 0.41 0.27 (1.5) +/+ + + + +
Poor
CCL227 2.50 2.59 (1.0) 0.25 0.25 (1.0) 0/0 _
CCL228 1.80 2.70 (1.5) 0.60 0.25 (2.4) + +/+ +
CloneA 0.52 2.67 (5.1) 2.50 0.59 (4.2) ++++/++++ ++++
CCL222 1.99 2.34 (1.2) ND ND 0/+
CCL220.1 1.33 0.98 (0.8) ND ND +/ND
MIP 101 0.42 1.84 (4.4) 1.55 0.32 (4.8) ++++/++++ ++++
aSuspensions ofcolon cells (2 x 106 ml-') were incubated for 90 min at 37°C with 10tLM [3H]daunorubicin (sp. act.
1 miCi/10pM) in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine and 25 mM HEPES (pH 7.25)
with glucose concentration of 11 mM. Verapamil (10 iLg ml-l) was added immediately before daunorubicin and
incubations were terminated by layering 0.5 ml cells over silicone and microcentrifuging at 12,000g for 1 min. Pellets
weredissolved inNaOHandcountedbyliquid scintillation spectrometry. Valuesarethemeansoftwodeterminations.
bIC5o values were determined using the SRB assay described in Methods. Verapamil (10 gml-') was added
immediately beforedoxorubicin. Cellswere treated for 3 h and SRBoptical densitydetermined on trichloroacetic acid
(10%) fixedcells,4daysafterdrug treatment. Valuesarethemeans ofno lessthanthreeexperiments. cDosemodifying
factors (DMF) were calculated as follows:
Drug Accumulation; nmoles daun/106 cells + verapamil DOX IC50; IC50 control
nmoles daun/106 cells control IC_u + verapamil
dmdrl mRNA levels were estimated byNorthern blot analysis, and are presented relative to the level expressed in MIP
101; 0, no mdrl mRNA detected; + ++ +, equivalent to MIP 101. Pgp biosynthesis was calculated by labelling cells
for 16 hwith35S-methionine followed byimmunoprecipitation with excess affinity purified mdrl antibody. Theimmune
complexes were separated in a 7.5% SDS-PAGE. The values shown are 0; no Pgp detected in repeated experiments,
+ +++ equivalent to MIP 101. eSurface expression determined using Mab 4E3.16 binding of live cells assessed in
FACS analysis. 'ND = not determined.
(Greenberger et al., 1988; Richert et al., 1988). Labelling of
cells for shorter periods (3 h) with 35S-methionine facilitates
resolution of both the immature and mature forms of the
P-glycoprotein (Figure 4, upper panel). Immunoprecipitation
of Pgp from cell lysates of CCL 228, Clone A and MIP 101
(Figure 4, upper panel) show both the 140 kd precursor and
170 kd mature Pgp, whilst the Moser cell line displays a
faster migrating mature P-glycoprotein (Figure 4). Since the
precursor 140 kD molecule of Moser migrates to the same
level as that observed in other lines expressing MDR, it is
likely that the altered mature P-glycoprotein in this cell line
results from underglycosylation. It is interesting to note that
Moser displays significant Pgp pump activity despite aberrant
processing of the immature form (Table II). Representation
of the 140 kd precursor in DLD-l is at comparable levels to
that of Moser and yet only minimal mature P-glycoprotein is
resolved in immunoprecipitation experiments (compare lanes,
Figure 4, upper panel). The difference in migration of the
170 kd Pgp in Moser and its under representation in DLD-1
is best resolved in experiments where cells were labelled for a
3 h period with 32P-orthophosphate. Immunoprecipitation of
phosphorylated Pgp in the same panel of cell lines (Figure 4,
lower panel) reveals minimal and aberrant signals in DLD-1
and Moser respectively. Most notable in these assays is the
resolution of a single 170 kD protein corresponding to the
mature 170 kD P-glycoprotein. From these results we con-
clude only the mature P-glycoprotein is phosphorylated in
constitutively expressed MDR.
Detection ofcell surface associated Pgp in colon cell lines
One explanation for the different MDR phenotypes displayed
by Moser and DLD-1 in the presence ofcomparable levels of
P-glycoprotein biosynthesis, is that the reduction in mature
(170 kD) Pgp observed in DLD-l results in the absence of
membrane associated product. To address this possibility we
have used a monoclonal antibody (4E3.16) recognising an
external epitope ofPgp, capable of binding P-glycoprotein on
live cells. Incubation of a representative panel of colon cell
lines with the fluorochrome tagged antibody, followed by
fluorescence activated cell sorting demonstrates the level of
expression of surface associated Pgp (Figure 5). In this study
DLD-1 showed minimal levels of detectable surface Pgp
(Figure 5, panel b) contrasting with the Moser cell line which
displayed high levels of surface staining (Figure 5, lane f),
comparable to that recorded in the most drug resistant colon
cell lines Clone A and MIP 101 (Figure 5, panels g and h
respectively). Comparative levels of surface Pgp within the
cell panel, directly correlated with the MDR phenotype esta-
blished in drug uptake assays (Table II).
Functional assessment ofMDR in colon cells
Colon cells expressed a range of differences with respect to
net daunorubicin accumulation and doxorubicin cytotoxicity
(Table II). Colon carcinoma cells accumulated between
0.42 nmoles daunorubicin/106 cells to 2.5 nmoles dauno-964 R. KRAMER et al.
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Figure 4 Immunoprecipitation of P-glycoprotein from a
representative panel of colon carcinoma cell lines following a
short labelling period (3 h) with 35S-methionine (upper panel) or
32P-orthophosphate (lower panel). P-glycoprotein is resolved as a
doublet (upper panel) representing the mature 170 kD glyco-
protein and the immature unglycosylated 140 kD precursor. Note
the faster migrating mature P-glycoprotein associated with Moser
(unlabelled arrow) and the absence of detectable mature P-
glycoprotein (170) in DLD-1 (upper panel). Parallel experiments
with immunoprecipitation of Pgp from 32P-orthophosphate cell
lysates results in detection of the mature 170 kD P-glycoprotein
(lower panel), once again demonstrating altered migration in the
Moser cell line.
rubicin/106 cells, with the lowest levels being found in mdrl
mRNA/Pgp positive colon cells lines. The doxorubicin con-
centration that inhibited colon cell growth by 50% (ICm; 3 h
drug exposure) varied as much as 50-fold among the various
colon cell lines, ranging from 0.05p1M to 2.5 1M, with mdrl
mRNA/Pgp-positive cells having the highest IC50 values.
Pgp function was estimated by determining the fold in-
crease in net [3H]-daunorubicin accumulation and doxoru-
bicin cytotoxicity (decreases in IC50 value) that was caused by
treating cells with an antagonist of Pgp (i.e. verapamil,
25 LM) (Table II). Verapamil treatment increased drug
accumulation in colon cell lines by 20 to 510%, and resulted
in a corresponding increase in doxorubicin cytotoxicity (i.e.
fold decrease in ICo value). The percentage increase in drug
accumulation and cytotoxicity was used to estimate Pgp
function, and was found to correlate with mdrl mRNA/Pgp
expression levels. For example, colon cell lines that had no
measurable mdrl mRNA or Pgp (e.g. CCL238, CX-1, HT29,
CCL227), exhibited no functional Pgp activity as determined
by the verapamil- inducible drug uptake and cytotoxicity
assays (Table II). Cells expressing the lowest detectable levels
of mdrl mRNA/Pgp (e.g. LoVo, CL187, CaCo-2, CCL220.1)
also had no measurable increases in drug accumulation or
cytotoxicity in response to verapamil. However, cell lines
expressing low to moderate levels of mdrl mRNA/Pgp (e.g.
CL188, CCL231, DLD-1), did exhibit a range (10-100%) of
verapamil-induced increases in drug accumulation and cyto-
toxicity. The highest levels of Pgp activity (>250%) were
found in those cell lines expressing the highest levels of mdrl
mRNA/Pgp (i.e. Moser, MIP 101, Clone A). Only 2/8 of the
well differentiated cell lines expressed the MDR phenotype as
defined by these criteria, and these well differentiated MDR
positive cell lines (i.e. CLI88 and CCL233) exhibited the
lowest measurable levels of functional activity (20-30%). In
contrast, 9/11 moderate and poorly differentiated cell lines
displayed functional MDR phenotypes exhibiting Pgp activi-
ties ranging from 20->500%.
Non-Pgp mechanisms ofMDR in colon carcinoma cells
Representative colon cell lines were analysed for cross-
resistance and chemosensitivity profiles against a battery of
chemotherapeutic drugs (Table III). In these studies, the cells
were exposed to drugs for 48 h. Cells expressing high consti-
tutive levels of mdrl mRNA/Pgp i.e. MIP 101, Clone A,
Moser, were cross-resistant to drugs normally associated with
the MDR phenotype e.g. vincristine, etoposide and doxoru-
bicin. The relative degree of drug resistance was determined
by comparing the IC50 values in these cells to a representative
Pgp-negative cell line e.g. CCL238. The drug sensitivity pro-
file of CCL 238 was not appreciably different to the sensitive
human leukaemia cell line HL60. The relative resistance (i.e.
IC50 of MDR+ cells/IC50 CCL238) of these high expressing
cell lines was proportional to the cellular levels of mdrl
mRNA/Pgp and ranged from 2.5 to 50-fold for doxorubicin
11 to 50-fold for vincristine and 5 to 10-fold for etoposide.
While, vincristine resistance correlated with the level of mdrl
mRNA/Pgp expression, a direct relationship between etopo-
side resistance and mdrl mRNA/Pgp expression could not be
established. For example, CCL228 expressed lower levels of
mdrl mRNA/Pgp compared to MIP 101, Clone A or Moser
(Table III) and were proportionally less resistant to vincris-
tine, and yet of the MDR positive cells, CCL228 was the
most resistant to etoposide. Moreover, the cell lines demon-
strating the highest levels of etoposide resitance i.e. CaCo-2
and CX-1 were not MDR-positive as shown by the lack of
mdrl expression as well as by functional assays. As might be
expected the MDR cells were not cross-resistant to 5-fluor-
ouracil, cisplatin or chlorambucil (Table III). Cells exhibiting
a modest degree of functional Pgp activity (Table II) ex-
pressed detectable but correspondingly lower levels of mdrl
mRNA/Pgp. These cells, CL188, DLD-1, CCL231, were not
cross-resistant to the standard MDR drugs. For example,
both mdrl mRNA and Pgp were detected in CCL231 cells at
levels that were proportional to the verapamil mediated in-
crease in 3H-daunorubicin accumulation of 80% (Table II).
However, CCL231 was equally sensitive to doxorobucin, vin-
cristine and etoposide compared to our non-Pgp reference
CCL238 colon carcinoma cell line. These observations sug-
gest that in colon cancer, other mechanisms of resistance e.g.,
altered topoisomerase, glutathione may also contribute to the
pattern of resistance particularly when mdrl mRNA/Pgp
when expressed at low levels. However at higher levels of
expression, mdrl mRNA/Pgp becomes the major determinant
of resistance.
Discussion
Multidrug resistance has been implicated as a contributing
factor in the intrinsic resistance of several solid tumours,
including colon, ever since the original observation by
Thiebaut et al. (1987) that the mdrl gene product was consti-
tutively expressed in the normal tissues from which these
tumours were derived. Subsequent studies by Fojo et al.
(1987b), Goldstein et al. (1989) and others, provided addi-
tional support for this by demonstrating that mdrl mRNA
was often present in the primary colon tumour specimens
before patients received chemotherapy. A recent report by
Weinstein et al. (1991) demonstrated that immunodetectable
Pgp was found in a high percentage of invasive carcinomaMULTIDRUG RESISTANCE IN COLORECTAL CANCER 965
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Figure 5 Surface expression of P-glycoprotein in colon carcinoma cell lines using monoclonal antibody 4E3.16 in FACS analysis.
a, HT29; b, DLD-1; c, CCL 229; d CL 188; e, CCL-231; f, Moser; g, Clone A; h, MIP 101. Unshaded area in each panel represents
surface Pgp detected on live cells with Mab 4E3.16. Shaded area in each panel represents analysis with class matched control
antibody IgG2a.
cells and in the lymph node metastasis of patients with colon
cancer. The present study extends these observations by
demonstrating that mdrl mRNA was also expressed in liver
metastasis. These findings demonstrate that colon carcinoma
cells not only retain the capacity to express the mdrl gene,
but that this characteristic of the normal colonic epithelium
can be maintained throughout all stages of colon tumour
progression. This observation is consistent with a recent
study in neuroblastoma patients in which Pgp was detected
in a high percentage of the advanced lesions (Chan et al.,
1991). The findings in neuroblastoma and colon cancer
patients provide a compelling basis for understanding why
metastatic disease is refractory to certain chemotherapeutic
drugs, particularly if the metastasis developed from primary
tumours that were derived from Pgp-expressing normal tis-
sues.
In this study, mdrl mRNA levels varied considerably in
colon tumours and in normal tissue, and is consistent with all
previous studies evaluating surgical material (Fojo et al.,
1987a,b; Lai et al., 1989; Goldstein et al., 1989). A relation-
ship between mdrl mRNA/Pgp expression and clinical drug
resistance is particularly hard to establish in colon cancer
because these patients rarely receive chemotherapy with
MDR-associated drugs. Therefore, one cannot relate expres-
sion levels with patient outcome in response to chemotherapy
as has been done in clinical studies involving patients with
soft tissue sarcomas (Gerlach et al., 1987), myelomas (Dalton
et al., 1989), or neuroblastomas (Chan et al., 1991). Previous
studies using surgical material from untreated colon cancer
patients have attempted to place significance on expression
levels in tumours that were higher than the levels expressed
in adjacent normal tissues. However, normal tissue mdrl
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Table III Chemosensitivity of human colorectal cell lines
IC50Values (igml-')a
Cell line DOXb VIN ETO S-FU CDDP CHLR
Well/moderately
differentiated
CCL238 0.12 0.02 1.1 8.6 1.0 4
CaCo-2 2.50 0.05 42.0 9.0 5.4 >100
CX-I 0.45 0.005 16.7 0.2 6.0 >100
HT-29 0.22 0.003 7.8 0.6 3.9 >100
LoVo 0.24 0.05 1.5 0.3 3.0 2
CL188 0.04 0.03 0.7 2.8 2.0 ND
Moderate/poorly
differentiated
CCL231 0.21 0.02 1.4 4.7 2.7 4
DLD-1 0.36 0.04 1.8 1.7 7.6 9
Moser 5.00 0.36 5.4 14 5.4 56
Poorly differentiated
CCL227 0.05 0.002 1.0 16 2.1 6
CCL228 0.30 0.22 9.9 9.8 2.1 >100
Clone A 3.0 0.80 8.7 5.4 5.4 85
MIP 101 4.5 1.00 5.5 8.5 4.3 85
Leukaemia
HL60 0.19 ND 2.1 6.3 5.7 24
aIC50 values were determined using the SRB assay, and were
calculated using the formulaT-TO/C-To, asdescribed in Methods. In all
experiments, log phase cells (1-2 x 104 cells per well in 96-well
microtitre plates) were treated with chemotherapeutic drugs for 48 h.
Values are the means of duplicate wells, and are representative of
multiple experiments. bAbbreviations used are DOX = doxorubicin;
VIN = vincristine; ETO = etoposide; 5-FU = 5-fluorouracil; CDDP =
cisplatin; and CHLR = chlorambucil.
mRNA levels were frequently higher than tumour levels
(Fojo et al., 1987b). It has never actually been established if
normal colon cells are also drug resistant, and at what level
of constitutive Pgp expression does resistance actually occur.
This may be important given that most of what we know
about Pgp and resistance has come from studies with cell
lines that were selected on the basis of functional criteria (i.e.
they survived treatment with escalating doses of chemo-
therapy). Thus we felt that human colon tumour cells offered
the best available model to study the relationship between
constitutive mdrl mRNA/Pgp expression and functional
resistance, and the possible relationship between mdrl
mRNA/Pgp expression and colon tumour progression. Cell
lines DLD-1, Clone A, Clone D, MIP 101, and Moser, all of
which express P-glycoprotein, were established from tumour
material prior to exposure from chemotherapeutic agents.
The colon carcinoma cell lines used in this study were
selected primarily on the basis of differentiation using esta-
blished criteria e.g. histology, carcinoembryonic antigen
secretion, these parameters are summarised in Table I. Pre-
vious studies have shown that poorly differentiated colon
carcinoma cells were the most aggressive as assessed using in
vitro adhesion and invasion assays (Daneker et al., 1989).
These in vitro studies support clinical observations which
have related poorly differentiated colon tumour histologies
with a poor prognosis and a greater likelihood of metastatic
involvement. It is clear from the biochemical data presented
that the most aggressive, poorly differentiated colon tumour
cell lines within the panel expressed the highest constitutive
levels of P-glycoprotein correlating with their relative func-
tionality recorded in drug uptake assays. In contrast to
previous reports (Mickley et al., 1989; Mizoguchi et al., 1990)
we find no correlation between differentiation status and the
MDR phenotype in the cell panel studied, but observe that
P-glycoprotein expression can be maintained in both well and
poorly differentiated colon cell lines. This observation is con-
sistent with that reported by Park et al. (1990). Although it
can be argued that cell lines are not representative of the in
vivo lesion, it should be considered that, since poorly differ-
entiated tumours represent approximately 5% of the colorec-
tal tumours resected, it is difficult to generate sufficient
numbers to definitively evaluate the differentiation/MDR
phenotype association using human tumour material. Inter-
estingly, Pgp was immunoprecipitated from some cell lines
where no MDR functionality was detected. This may reflect
the limitations ofsensitivity of the assays used or the require-
ment for a threshold level of Pgp expression to acquire func-
tional drug resistance. However, moderate/well differentiated
colon cell lines HT29 and CCL238 consistently displayed an
absence of detectable mdrl message or immunoprecipitable
Pgp and demonstrated a lack of MDR functionality in
repeated assays consistent with results reported by Spoelstra
et al. (1991). The amount of mature 170 kD P-glycoprotein
resolved in protein standardised immunoprecipitation was
directly reflected by the phosphorylation status of Pgp,
revealing an absolute correlation with MDR functionality
within the colon carcinoma cell panel studied.
Previous characterisation of the biosynthesis of Pgp has
identified a 140kD precursor molecule which is processed,
via N-linked glycosylation, to a 170 kD species identified as
the mature P-glycoprotein (Greenberger et al., 1988; Richert
et al., 1988). Despite the altered maturation of Pgp in the
Moser cell line the mature form is found to be phosphorylat-
ed and cell surface associated establishing the MDR pheno-
type displayed by Moser in functional assays. In contrast,
DLD-1 displayed only minimal detectable functional Pgp
activity despite relatively high expression levels of mdrl
mRNA in Northern blot analysis. Consistent with this obser-
vation is the lack of mature Pgp (170 kD) found in this cell
line despite detection of comparable levels of the precursor
molecule (140 kD) to that found in other cell lines within the
panel e.g. Moser. This apparent lack of processing of the
DLD-1 Pgp is further reflected in the absence of phos-
phorylated Pgp and the lack of P-glycoprotein at the cell
surface. The correlation observed between the phosphoryla-
tion status and membrane association of Pgp with the MDR
phenotype implicates both of these factors as important in
establishing cellular drug resistance. In all mdrl immuno-
precipitation protocols involving 32P-orthophosphate label-
ling, Pgp was resolved as a single band comigrating with the
mature 170kD P-glycoprotein. From these results we con-
clude that only the mature form of P-glycoprotein is phos-
phorylated in colon cells.
The functional significance of Pgp processing may be par-
ticularly important in non-selected, constitutively expressing
cells and tumours. This possibility further complicates
attempts to attribute the clinical resistance of colon cancer
solely to changes in the expression of mdrl mRNA and/or
detection of Pgp in immunohistochemistry or immunoprecip-
itation protocols. Although our results, showing a high fre-
quency of mdrl mRNA/Pgp expression in colon tumour
specimens and colon carcinoma cell lines supports a role for
MDR in the clinical resistance of colon carcinomas, we also
report that the low constitutive levels of Pgp expressed in
many colon carcinoma cells may not be sufficient to confer
resistance. Moreover, mdrl mRNA/Pgp expression levels cor-
related poorly with etoposide resistance, and several colon
carcinoma cell lines with appreciable levels of expression and
demonstrated Pgp activity (e.g. CCL 231) were no more
resistant to MDR drugs (e.g. vincristine) than were Pgp-
negative colon cell lines. These observations are consistent
with the view that multiple mechanisms in addition to Pgp
(e.g. topoisomerase, 6-alkylguanine-DNA-alkyltransferase,
glutathione peroxidase) contribute to the overall resistance of
colorectal cancer (Kramer et al., 1988; Redmond et al.,
1991).
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